Victory Square Portfolio Company Hydreight Adds Semaglutide to Product Offerings

• Studies have shown that Semaglutide injections can be used together with diet and exercise to help control your blood sugar and help lose weight and keep the weight off. 
• Nurses can now support patients with regular injections pursuant to a physician’s order and help improve patient outcomes. 
• Hydreight provides an integrated, comprehensive mobile platform that connects healthcare professionals and their patients with pharmacies in the United States. 
  

VANCOUVER, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Victory Square Technologies Inc. (“Victory Square'') (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to announce that portfolio company Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), a mobile clinical network and medical platform which enables flexible, at-home medical services across 50 states in the United States, is excited to announce that healthcare providers and their patients now have access to Semaglutide through the Hydreight platform. 

Semaglutide injections are commonly used to treat type 2 diabetes. It can also be used together with diet and exercise to help control blood sugar and has become popular to help with weight management. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and is only available with a doctor’s prescription and needs to be injected on a regular basis. 

According to Goldman Sachs, it is projected that by 2030, the global market for anti-obesity medications (AOMs) could grow by more than 16 times to $100 billion. Based on current trends, over half of the global population will be overweight or obese by 2035, compared to 38% in 2020, according to a World Obesity Atlas 2023 forecast.¹

Shane Madden, CEO of Hydreight commented, “This is a significant inflection point for Hydreight and a pivotal point for our business. We have seen huge demand in the United States for medications like Semaglutide to help with weight management.  Our revolutionary technology platform allows doctors and nurses to connect with patients and pharmacy networks to provide continuous care and improve patient outcomes. Adding access to Semaglutide through our platform is the first step in our shift from preventative medicine to essential healthcare, and we are only just getting started.”